Home> Latest Approval >Market >Main Body

  • Latest Approval

Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's Disease

2015-11-26 10:34
Impax
Read:568 Favorite  1
  Share
相关阅读
You may interest

Copyright©2020 药渡经纬信息科技(北京)有限公司 电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)

药渡APP Drug A-Z
药渡APP
药渡微信二维码
微信二维码